Biomarin Pharmaceutical (BMRN) Enterprise Value (2009 - 2026)

Biomarin Pharmaceutical has disclosed Enterprise Value across 18 years of filings, most recently posting -$2.2 billion for Q1 2026.

• Quarterly Enterprise Value fell 74.67% year-over-year to -$2.2 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.2 billion (down 74.67% YoY) and the FY2025 annual result came in at -$1.6 billion, down 37.17% from the prior year.
• Enterprise Value fell to -$2.2 billion in Q1 2026, from -$1.6 billion in the prior quarter.
• Over five years, Enterprise Value peaked at -$930.4 million in Q3 2024 and troughed at -$2.2 billion in Q1 2026.
• A 5-year average of -$1.3 billion and a median of -$1.2 billion in 2023 frame the typical range for Enterprise Value.
• Annual changes were most pronounced in 2024 — Enterprise Value climbed 17.36% — and 2026, when it plunged 74.67%.
• Tracing BMRN's Enterprise Value over 5 years: stood at -$1.3 billion in 2022, then advanced by 16.86% to -$1.1 billion in 2023, then fell by 5.95% to -$1.1 billion in 2024, then tumbled by 37.17% to -$1.6 billion in 2025, then tumbled by 42.41% to -$2.2 billion in 2026.
• Business Quant data shows BMRN's Enterprise Value at -$2.2 billion in Q1 2026, -$1.6 billion in Q4 2025, and -$1.5 billion in Q3 2025.